Annual EBIT
-$12.65 M
+$10.09 M+44.36%
31 December 2023
Summary:
Fennec Pharmaceuticals annual earnings before interest & taxes is currently -$12.65 million, with the most recent change of +$10.09 million (+44.36%) on 31 December 2023. During the last 3 years, it has risen by +$5.45 million (+30.10%). FENC annual EBIT is now -370.03% below its all-time high of $4.68 million, reached on 31 December 2011.FENC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$4.71 M
-$201.00 K-4.46%
30 September 2024
Summary:
Fennec Pharmaceuticals quarterly earnings before interest & taxes is currently -$4.71 million, with the most recent change of -$201.00 thousand (-4.46%) on 30 September 2024. Over the past year, it has dropped by -$3.70 million (-365.88%). FENC quarterly EBIT is now -133.96% below its all-time high of $13.87 million, reached on 31 March 2024.FENC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$2.88 M
-$3.70 M-56.18%
30 September 2024
Summary:
Fennec Pharmaceuticals TTM earnings before interest & taxes is currently $2.88 million, with the most recent change of -$3.70 million (-56.18%) on 30 September 2024. Over the past year, it has increased by +$19.88 million (+116.97%). FENC TTM EBIT is now -66.34% below its all-time high of $8.57 million, reached on 30 September 2012.FENC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FENC EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +44.4% | -365.9% | +117.0% |
| 3 y3 years | +30.1% | -14.0% | +117.9% |
| 5 y5 years | -21.5% | -152.8% | +123.2% |
FENC EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +44.4% | -134.0% | +40.9% | -56.2% | +111.8% |
| 5 y | 5 years | -21.5% | +44.4% | -134.0% | +40.9% | -56.2% | +111.8% |
| alltime | all time | -370.0% | +44.4% | -134.0% | +40.9% | -66.3% | +111.8% |
Fennec Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.71 M(+4.5%) | $2.88 M(-56.2%) |
| June 2024 | - | -$4.51 M(-132.5%) | $6.58 M(+1.7%) |
| Mar 2024 | - | $13.87 M(-885.0%) | $6.47 M(-151.2%) |
| Dec 2023 | -$12.65 M(-44.4%) | -$1.77 M(+74.8%) | -$12.65 M(-25.6%) |
| Sept 2023 | - | -$1.01 M(-78.1%) | -$17.00 M(-29.0%) |
| June 2023 | - | -$4.62 M(-12.1%) | -$23.96 M(-1.6%) |
| Mar 2023 | - | -$5.25 M(-14.1%) | -$24.35 M(+7.1%) |
| Dec 2022 | -$22.74 M(+32.0%) | -$6.11 M(-23.3%) | -$22.74 M(+8.3%) |
| Sept 2022 | - | -$7.97 M(+58.9%) | -$20.99 M(+22.4%) |
| June 2022 | - | -$5.01 M(+37.9%) | -$17.15 M(+6.3%) |
| Mar 2022 | - | -$3.64 M(-16.7%) | -$16.13 M(-6.3%) |
| Dec 2021 | -$17.22 M(-4.9%) | -$4.37 M(+5.7%) | -$17.22 M(+7.1%) |
| Sept 2021 | - | -$4.13 M(+3.5%) | -$16.08 M(-11.4%) |
| June 2021 | - | -$3.99 M(-15.6%) | -$18.15 M(-4.5%) |
| Mar 2021 | - | -$4.73 M(+46.5%) | -$19.00 M(+4.9%) |
| Dec 2020 | -$18.10 M(+39.1%) | -$3.23 M(-47.9%) | -$18.11 M(-2.3%) |
| Sept 2020 | - | -$6.20 M(+28.0%) | -$18.53 M(+30.6%) |
| June 2020 | - | -$4.84 M(+26.3%) | -$14.20 M(+0.2%) |
| Mar 2020 | - | -$3.83 M(+5.0%) | -$14.16 M(+8.9%) |
| Dec 2019 | -$13.01 M(+25.0%) | -$3.65 M(+96.1%) | -$13.01 M(+4.4%) |
| Sept 2019 | - | -$1.86 M(-61.3%) | -$12.46 M(-7.3%) |
| June 2019 | - | -$4.81 M(+79.6%) | -$13.45 M(+19.8%) |
| Mar 2019 | - | -$2.68 M(-13.7%) | -$11.22 M(+11.0%) |
| Dec 2018 | -$10.41 M(+49.7%) | -$3.10 M(+9.0%) | -$10.11 M(+6.2%) |
| Sept 2018 | - | -$2.85 M(+10.1%) | -$9.52 M(+7.5%) |
| June 2018 | - | -$2.59 M(+65.0%) | -$8.86 M(+14.3%) |
| Mar 2018 | - | -$1.57 M(-37.7%) | -$7.75 M(+11.5%) |
| Dec 2017 | -$6.95 M(+142.1%) | -$2.52 M(+15.1%) | -$6.95 M(+24.5%) |
| Sept 2017 | - | -$2.19 M(+47.8%) | -$5.58 M(+41.0%) |
| June 2017 | - | -$1.48 M(+91.8%) | -$3.96 M(+24.2%) |
| Mar 2017 | - | -$771.00 K(-32.7%) | -$3.19 M(+11.0%) |
| Dec 2016 | -$2.87 M(+51.9%) | -$1.15 M(+103.2%) | -$2.87 M(+26.1%) |
| Sept 2016 | - | -$564.00 K(-20.2%) | -$2.28 M(+11.0%) |
| June 2016 | - | -$707.00 K(+55.7%) | -$2.05 M(+8.4%) |
| Mar 2016 | - | -$454.00 K(-17.6%) | -$1.89 M(+0.1%) |
| Dec 2015 | -$1.89 M(-34.3%) | -$551.00 K(+63.0%) | -$1.89 M(-11.3%) |
| Sept 2015 | - | -$338.00 K(-38.4%) | -$2.13 M(-11.7%) |
| June 2015 | - | -$549.00 K(+21.5%) | -$2.41 M(-13.6%) |
| Mar 2015 | - | -$452.00 K(-42.9%) | -$2.79 M(-3.0%) |
| Dec 2014 | -$2.88 M(+49.0%) | -$791.00 K(+27.8%) | -$2.88 M(-39.4%) |
| Sept 2014 | - | -$619.00 K(-33.4%) | -$4.75 M(-19.4%) |
| June 2014 | - | -$930.00 K(+73.2%) | -$5.90 M(+0.1%) |
| Mar 2014 | - | -$537.00 K(-79.8%) | -$5.89 M(0.0%) |
| Dec 2013 | -$1.93 M(-62.6%) | -$2.67 M(+50.9%) | -$5.89 M(-39.5%) |
| Sept 2013 | - | -$1.77 M(+90.5%) | -$9.74 M(+11.5%) |
| June 2013 | - | -$927.00 K(+72.6%) | -$8.74 M(+3.9%) |
| Mar 2013 | - | -$537.00 K(-91.8%) | -$8.41 M(+63.0%) |
| Dec 2012 | -$5.16 M | -$6.51 M(+752.2%) | -$5.16 M(-160.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | -$764.00 K(+26.9%) | $8.57 M(+2.1%) |
| June 2012 | - | -$602.00 K(-122.2%) | $8.39 M(-0.4%) |
| Mar 2012 | - | $2.71 M(-62.4%) | $8.42 M(+79.8%) |
| Dec 2011 | $4.68 M(-159.9%) | $7.22 M(-864.9%) | $4.68 M(-171.3%) |
| Sept 2011 | - | -$944.00 K(+65.0%) | -$6.57 M(+0.4%) |
| June 2011 | - | -$572.00 K(-44.0%) | -$6.54 M(-23.4%) |
| Mar 2011 | - | -$1.02 M(-74.7%) | -$8.54 M(+8.3%) |
| Dec 2010 | -$7.82 M(+176.4%) | -$4.04 M(+340.0%) | -$7.89 M(+134.2%) |
| Sept 2010 | - | -$917.00 K(-64.3%) | -$3.37 M(+33.4%) |
| June 2010 | - | -$2.57 M(+601.9%) | -$2.52 M(+175.5%) |
| Mar 2010 | - | -$366.00 K(-175.5%) | -$916.00 K(-63.4%) |
| Dec 2009 | -$2.83 M(-79.6%) | $485.00 K(-755.4%) | -$2.50 M(-55.5%) |
| Sept 2009 | - | -$74.00 K(-92.3%) | -$5.63 M(-36.4%) |
| June 2009 | - | -$961.00 K(-50.8%) | -$8.85 M(-22.4%) |
| Mar 2009 | - | -$1.95 M(-26.1%) | -$11.40 M(-17.9%) |
| Dec 2008 | -$13.89 M(-2.1%) | -$2.64 M(-20.0%) | -$13.89 M(-3.7%) |
| Sept 2008 | - | -$3.30 M(-6.0%) | -$14.43 M(-1.1%) |
| June 2008 | - | -$3.51 M(-20.9%) | -$14.58 M(+0.5%) |
| Mar 2008 | - | -$4.44 M(+39.5%) | -$14.51 M(+2.3%) |
| Dec 2007 | -$14.19 M(-25.6%) | -$3.18 M(-8.0%) | -$14.19 M(-21.2%) |
| Sept 2007 | - | -$3.46 M(+0.5%) | -$18.02 M(-6.8%) |
| June 2007 | - | -$3.44 M(-16.4%) | -$19.33 M(-2.7%) |
| Mar 2007 | - | -$4.12 M(-41.3%) | -$19.87 M(+4.2%) |
| Dec 2006 | -$19.06 M(+3.9%) | -$7.01 M(+46.9%) | -$19.06 M(+10.6%) |
| Sept 2006 | - | -$4.77 M(+19.9%) | -$17.24 M(-0.2%) |
| June 2006 | - | -$3.98 M(+20.3%) | -$17.28 M(-5.3%) |
| Mar 2006 | - | -$3.31 M(-36.3%) | -$18.24 M(-0.6%) |
| Dec 2005 | -$18.35 M(+98.1%) | -$5.19 M(+8.1%) | -$18.35 M(+39.4%) |
| Sept 2005 | - | -$4.80 M(-2.8%) | -$13.16 M(+14.3%) |
| June 2005 | - | -$4.94 M(+44.6%) | -$11.52 M(+23.6%) |
| Mar 2005 | - | -$3.42 M(+8.2%) | -$9.32 M(-13.5%) |
| Sept 2004 | - | -$3.16 M(+15.1%) | -$10.77 M(+16.4%) |
| June 2004 | -$9.26 M(+39.2%) | -$2.74 M(+1.3%) | -$9.25 M(+5.6%) |
| Mar 2004 | - | -$2.71 M(+25.4%) | -$8.76 M(+10.2%) |
| Dec 2003 | - | -$2.16 M(+31.9%) | -$7.95 M(+14.1%) |
| Sept 2003 | - | -$1.64 M(-27.4%) | -$6.97 M(+7.6%) |
| June 2003 | -$6.65 M(+78.9%) | -$2.26 M(+18.7%) | -$6.48 M(+20.1%) |
| Mar 2003 | - | -$1.90 M(+61.4%) | -$5.39 M(+22.5%) |
| Dec 2002 | - | -$1.18 M(+2.7%) | -$4.40 M(+12.3%) |
| Sept 2002 | - | -$1.15 M(-2.2%) | -$3.92 M(+5.2%) |
| June 2002 | -$3.72 M(+40.4%) | -$1.17 M(+28.8%) | -$3.73 M(-28.4%) |
| Mar 2002 | - | -$909.60 K(+30.8%) | -$5.21 M(+21.2%) |
| Dec 2001 | - | -$695.30 K(-27.1%) | -$4.30 M(+3.3%) |
| Sept 2001 | - | -$953.30 K(-64.0%) | -$4.16 M(+29.7%) |
| June 2001 | -$2.65 M(+65.0%) | -$2.65 M(<-9900.0%) | -$3.21 M(+474.0%) |
| Mar 2001 | - | $0.00(-100.0%) | -$558.80 K(0.0%) |
| Dec 2000 | - | -$558.80 K(<-9900.0%) | -$558.80 K(<-9900.0%) |
| Sept 2000 | - | $0.00 | $0.00 |
| June 2000 | -$1.61 M | - | - |
FAQ
- What is Fennec Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual EBIT year-on-year change?
- What is Fennec Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly EBIT year-on-year change?
- What is Fennec Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals TTM EBIT year-on-year change?
What is Fennec Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of FENC is -$12.65 M
What is the all time high annual EBIT for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual earnings before interest & taxes is $4.68 M
What is Fennec Pharmaceuticals annual EBIT year-on-year change?
Over the past year, FENC annual earnings before interest & taxes has changed by +$10.09 M (+44.36%)
What is Fennec Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of FENC is -$4.71 M
What is the all time high quarterly EBIT for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly earnings before interest & taxes is $13.87 M
What is Fennec Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, FENC quarterly earnings before interest & taxes has changed by -$3.70 M (-365.88%)
What is Fennec Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of FENC is $2.88 M
What is the all time high TTM EBIT for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high TTM earnings before interest & taxes is $8.57 M
What is Fennec Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, FENC TTM earnings before interest & taxes has changed by +$19.88 M (+116.97%)